The value of hyoscine butylbromide in pelvic MRI.
OBJECTIVE
To evaluate the effect of hyoscine butylbromide (HBB) on image quality and lesion and organ visualization in pelvic magnetic resonance imaging (MRI) MATERIALS AND METHODS: A prospective, ethically approved study was undertaken of 47 patients attending for pelvic MRI at a cancer centre. T2-weighted transverse and sagittal sequences were performed before and after intravenous injection of 20 mg HBB. Three radiologists independently scored anonymized image series for overall image quality, visualization of pelvic lesions and visualization of individual pelvic organs. Statistical analysis was performed to assess improvements in radiologists' scores post-HBB administration. Radiologists also assessed pre-HBB administration T1-weighted images for degree of bowel peristalsis to determine whether this could predict improvement in post-HBB T2-weighted image scores. Side effects of HBB were recorded using a patient questionnaire.


RESULTS
Radiologists' scores for image quality and lesion visualization were significantly higher on the post-HBB administration T2-weighted series (p<0.0005). Scores for the visualization of the bladder, rectum, pelvic bowel, prostate, and seminal vesicles (all p<0.0005), cervix (p=0.019) and vagina (p=0.0001) were also significantly higher post-HBB administration. Scores for the degree of peristalsis on T1-weighted images were not related to improvement in image quality or lesion visualization on T2-weighted images post-HBB administration. Side effects of HBB were mild and self-limiting.


CONCLUSIONS
Intravenous HBB administration improves image quality and lesion visualization in oncological pelvic MRI and is recommended for routine use.
Johnson
W
W
Department of Diagnostic Radiology, Christie Hospital NHS Trust, Withington, Manchester, UK.
Taylor
M B
MB
Carrington
B M
BM
Bonington
S C
SC
Swindell
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002086:Butylscopolammonium Bromide; D003287:Contrast Media; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists; D010386:Pelvic Neoplasms / Q000175:diagnosis*; D010528:Peristalsis; D011446:Prospective Studies
D003287:Contrast Media; D018727:Muscarinic Antagonists; D002086:Butylscopolammonium Bromide